Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .
[Comparison of different drugs on the treatment of benign prostate hyperplasia].
OBJECTIVE To compare the differences of the efficacy and different therapeutic drugs on the treatment of benign prostatic hyperplasia ( BPH ) in order to ensure the optimal indication for different BPH patients . METHODS A r and omized , parallel-controlled , multicenter clinical trial was conducted . From September 2002 to December 2003 906 BPH patients were enrolled into 7 therapeutic groups , including selective-adrenoceptor antagonist ( terazosin , doxazosin tamsulosin and naftopidil ) , 5 alpha-reductase inhibitor ( finasteride and epristeride ) and natural product ( cernilton ) . International Prostate Symptom Score ( IPSS ) and Quality of Life ( QOL ) , uroflowmetry , total prostatic volume ( TPV ) and transitional zone volume and residual urine  were used as efficacy criteria . RESULTS According to the baseline , the IPSS and Qmax were significantly correlated to the prostatic volume and transitional zone volume ( P < 0.01 ) . At average follow-up of 6 months , significant improvements in IPSS , QOL , Qmax and residual urine volume were observed in each therapeutic group , and no difference in IPSS improvement was found among the groups . Prostatic volume and transitional zone volume were significant decreased in 5alpha-reductase inhibitor groups ( P < 0.05 ) . In patients with baseline TPV greater than 35.5 cm3 , the improvement of Qmax was more significant than that in patients with TPV less than 35.5 cm3 in finasteride group ( P < 0.01 ) ( 5.7 ml/s and 2.2 ml/s respectively ) , and more significant symptomatic improvements were also found in cernilton , doxazosin and naftopidil group . In each group , the improvement of symptom were more significant in patients with IPSS higher than 20 points ( P < 0.01 ) . CONCLUSIONS Each drug observed in this study can improve the subjective and objective symptoms significantly for BPH patients , especially for patients with higher IPSS baseline . When using 5alpha-reductase inhibitor , prostatic volume can be decreased significantly and more obviously subjective and objective improvement can be found in the patients with TPV greater than 35.5 cm3
Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .